A phase I, randomized, double-blind, placebo-controlled, single-dose, sequential-group escalation, first in human, single-center study to evaluate the safety, tolerability, and pharmacokinetics parameters of ONO-4232 versus placebo in healthy volunteers

Trial Profile

A phase I, randomized, double-blind, placebo-controlled, single-dose, sequential-group escalation, first in human, single-center study to evaluate the safety, tolerability, and pharmacokinetics parameters of ONO-4232 versus placebo in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs ONO 4232 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; First in man
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 29 Mar 2016 New trial record
    • 18 Mar 2016 Results (n=76) published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top